Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOTRIN IB vs SPRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Relief of minor aches and pains due to headache, toothache, backache, menstrual cramps, muscle aches, or minor pain of arthritis,Reduction of fever
Short-term management of moderate to moderate-severe acute pain (FDA-approved indication)
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.
Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.
Terminal elimination half-life is approximately 2 hours (range 1.8–2.5 hours) in adults. In patients with hepatic impairment or advanced age, half-life may be prolonged. The short half-life supports dosing every 6–8 hours for analgesia.
Terminal elimination half-life is 5-6 hours in adults with normal renal function; may be prolonged to 13-14 hours in elderly patients and 15-20 hours in patients with renal impairment.
Primarily hepatic via cytochrome P450 2C9 (CYP2C9) and, to a lesser extent, CYP2C8; undergoes glucuronidation.
Primarily hepatic via conjugation (glucuronidation) and oxidation (CYP2C9 minor). Metabolites are inactive.
Renal excretion of conjugated metabolites (primarily glucuronide and sulfate) accounts for approximately 90% of an absorbed dose; less than 1% is excreted unchanged. Biliary/fecal elimination constitutes about 10%.
Renal excretion of unchanged drug and metabolites; after intravenous administration, approximately 92% of the dose is recovered in urine (50% as unchanged ketorolac, 40% as glucuronide conjugates) and 6% in feces.
Approximately 99% bound to plasma albumin.
99% bound to plasma proteins, primarily albumin (saturable at high concentrations).
Apparent volume of distribution is 0.15 L/kg (range 0.10–0.20 L/kg), consistent with low tissue penetration and high plasma protein binding.
0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
Oral: ~80% (rapidly and completely absorbed; first-pass metabolism reduces absolute bioavailability to 80% of the dose).
Intranasal: approximately 75-80% relative to intravenous administration.
GFR 30-60 m L/min: no adjustment needed; GFR 10-29 m L/min: reduce dose by 25-50%; GFR <10 m L/min: avoid use or reduce dose by 50%.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-60 m L/min), reduce total daily dose by 50% and monitor for renal toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Contraindicated in Child-Pugh Class C cirrhosis. For mild to moderate hepatic impairment (Child-Pugh A or B), reduce total daily dose by 50% and monitor for signs of bleeding or hepatic toxicity.
6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day or single doses not exceeding 400 mg.
Not recommended for use in pediatric patients (safety and efficacy not established).
Initiate at the lowest effective dose, typically 200-400 mg every 6-8 hours; maximum 1200 mg/day; monitor renal function and potential for GI bleeding.
Elderly patients may have increased risk of GI bleeding and renal toxicity. Use lowest effective dose and shortest duration; monitor renal function and adjust dose based on estimated glomerular filtration rate (e GFR).
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk. Additionally, NSAIDs cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk is increased with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions such as Stevens-Johnson syndrome; avoid use in late pregnancy
Cardiovascular risk: May increase risk of serious cardiovascular thrombotic events.,Gastrointestinal risk: Can cause serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: Monitor renal function; avoid in patients with advanced renal disease.,Hepatic effects: Elevations in liver enzymes; discontinue if signs of hepatic injury occur.,Anaphylactoid reactions: Can occur in patients without prior exposure.,Pregnancy: Avoid in late pregnancy due to risk of premature closure of ductus arteriosus.
Hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; active peptic ulcer or gastrointestinal bleeding; advanced renal disease
Hypersensitivity to ketorolac or any NSAID,Active peptic ulcer disease or GI bleeding,Advanced renal impairment (creatinine clearance <30 m L/min),Patients at risk for bleeding or receiving anticoagulants,Labor and delivery (risk of fetal harm),Treatment of perioperative pain in CABG surgery,Concomitant use with other NSAIDs or aspirin,Intrathecal or epidural administration (contains alcohol)
Concomitant intake of alcohol may increase risk of gastrointestinal bleeding. No specific food restrictions; however, taking with food may reduce GI irritation. Avoid grapefruit juice? No significant interaction known.
No specific food interactions. Avoid alcohol as it may increase risk of GI bleeding. Take with food or milk to minimize GI upset.
First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dysfunction. Third trimester: Known risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, oligohydramnios, and necrotizing enterocolitis. Use contraindicated after 30 weeks gestation.
Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if potential benefit justifies risk.
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Amount ingested by infant <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects and renal function.
Excreted in human milk in low amounts. M/P ratio not available. Consider risk of infant NSAID exposure; use with caution, especially in neonates.
Increased volume of distribution and renal clearance in pregnancy may reduce serum concentrations. However, due to fetal risks, dose adjustments are not recommended; instead, avoid use after 30 weeks and limit to lowest effective dose with shortest duration in earlier trimesters.
No specific dose adjustments recommended for pharmacokinetic changes in pregnancy. Use lowest effective dose for shortest duration.
Motrin IB (ibuprofen) is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, fever, and inflammation. Onset of analgesia is within 30-60 minutes. It is more effective than acetaminophen for inflammatory pain. Maximum single OTC dose is 400 mg; maximum daily OTC dose is 1200 mg. Chronic use increases risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with significant renal impairment (e GFR <30), active peptic ulcer disease, or prior hypersensitivity to NSAIDs. Use with caution in patients with hypertension, heart failure, or on anticoagulants. Ibuprofen may reduce the cardioprotective effect of low-dose aspirin if taken simultaneously; separate dosing by at least 2 hours.
SPRIX (ketorolac tromethamine) is an NSAID nasal spray for acute pain. Use lowest effective dose for shortest duration. Avoid in patients with active peptic ulcer, recent GI bleeding, renal impairment (Cr Cl <30 m L/min), or at risk of bleeding. Contraindicated in patients with aspirin or NSAID allergy, and in patients with or at risk of intracranial bleeding. Monitor renal function and GI symptoms. Not for use in pediatric patients. Maximum duration is 5 days.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg (6 tablets of 200 mg) in 24 hours.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult a doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Do not take with other NSAIDs (e.g., naproxen, aspirin) unless directed by a healthcare provider.,Seek medical attention immediately if signs of allergic reaction (rash, hives, swelling, difficulty breathing) or stomach bleeding (black/bloody stools, vomiting blood) occur.
Use exactly as prescribed; do not exceed 5 days of therapy.,Spray into nostril; do not sniff deeply after spraying.,Avoid alcohol and other NSAIDs while using this medication.,Seek medical help if you experience signs of bleeding, stomach pain, or allergic reaction.,Store at room temperature; do not refrigerate or freeze.,Tell your doctor about all other medications you take, especially blood thinners or other NSAIDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOTRIN IB vs SPRIX, answered by our medical review team.
MOTRIN IB is a NSAID Analgesic that works by Reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. SPRIX is a NSAID Analgesic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOTRIN IB and SPRIX depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOTRIN IB is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg in 24 hours.. The standard adult dose of SPRIX is: Intranasal: 31.5 mg (1 spray) in one nostril, may repeat after 30 minutes; maximum 63 mg (2 sprays) per dose. Subsequent doses every 6-8 hours as needed; maximum 126 mg (4 sprays) per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOTRIN IB and SPRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOTRIN IB is classified as Category C. First trimester: Increased risk of miscarriage and cardiac defects (odds ratio 1.86 for cardiovascular malformations). Second trimester: Risk of oligohydramnios and fetal renal dys. SPRIX is classified as Category C. Pregnancy Category C. Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. No adequate studies in first two trimesters; use only if p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.